GlaxoSmithKline reported 6.47B in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alcon AG ALC:SW 961M 614M
Amgen AMGN:US $ 5203M 1325M
Artemis Alpha ATS:LN 7.15M 672K
AstraZeneca AZN:LN 4817M 945M
Bayer BAYN:GR € 3412M 2373M
Biogen BIIB:US $ 2646.6M 897.3M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Eli Lilly And LLY:US $ 2622.9M 163.7M
Fresenius FRE:GR € 2129M 52M
Fresenius Medical Care FME:GR € 1025M 148.34M
Genmab GEN:DC DK 9071M 114M
Gilead Sciences GILD:US $ 7000M 2704M
GlaxoSmithKline GSK:LN 6465M 4502M
Glaxosmithkline GSK:US $ 6465M 4502M
Hikma Pharmaceutical HIK:LN 23M 1000K
Lonza Group LONN:SW 1.53B 56M
Merck MRK:GR € 1580M 241M
Novartis NOVN:VX SF 3625M 10227M
Orion ORNBV:FH € 86.1M 172.6M
Philips PHIA:NA € 1258M 187M
Recordati REC:IM € 373.76M 112.33M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M